ArticleFrontiers in pharmacology2026
Sinus bradycardia after intravenous methylprednisolone pulse therapy in patients with thyroid-associated ophthalmopathy.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Intravenous methylprednisolone pulse (IVMP) therapy is the first-line treatment for active moderate-to-severe and very severe thyroid-associated ophthalmopathy (TAO). IVMP-induced sinus bradycardia has not been previously reported in patients with TAO in the published English-language literature. This study aimed to determine the prevalence and characteristics of IVMP-induced bradycardia in patients with TAO and to analyze the associated factors. Methods: This retrospective cohort study was conducted on 166 patients with TAO who received IVMP therapy at Shandong Provincial Hospital between January 2023 and March 2026. Clinical data were collected during hospitalization. Sinus bradycardia was defined as a resting heart rate below 60 beats/min. The prevalence and features of bradycardia were evaluated. Furthermore, multivariable Cox regression and sensitivity analyses were performed to identify independently associated factors. Results: Bradycardia occurred in 28.9% (48/166) of individuals receiving IVMP therapy. Among those with bradycardia, 79.2% (38/48) experienced their first episode within 3 days of initiating treatment, and 12.5% (6/48) had two episodes during IVMP. The mean lowest heart rate of first bradycardia was 46.9 beats/min, representing a 42.1% decrease from baseline (80.9 beats/min). The first episodes of bradycardia lasted 2.8 days on average and within 4 days mostly. No clinically significant decrease in diastolic blood pressure was observed during the first bradycardia episodes, despite statistical significance. Multivariable Cox regression analysis identified five factors independently associated with bradycardia. Heart rate (HR 0.971, 95% CI 0.945-0.998, Conclusion: Bradycardia commonly occurred during IVMP therapy in individuals with TAO. Heart rate, BMI, and periorbital edema were significantly and inversely associated with sinus bradycardia, whereas cardiac disease and TSH showed significant positive associations. These findings highlight the importance of cardiac monitoring in individuals at high risk of bradycardia during IVMP treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.